TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02070406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
Description: Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: NY-ESO-1157-165 peptide pulsed DC vaccine given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00965406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK and intensive insulin therapy
Description: GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIK and intensive insulin therapy
Description: GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
Study: NCT00664755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine patch
Description: Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study.
Study: NCT03799328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi-OIT
Description: low dose OIT to multiple foods
Study: NCT03017365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable Resistance Training
Description: traditional machine-based resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable Resistance Training
Description: free weight resistance training using unstable devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor/Abductor Resistance Training
Description: machine-based adductor/abductor resistance training
Study: NCT03591094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04497298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
Description: Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Physiological saline solution (0.9% NaCl)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline solution (0.9% NaCl)
Study: NCT02527655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice-Based Physical Activity and Active Transportation
Study: NCT03591055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA, medication review, exercise and cognitive stimulation
Description: Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
Study: NCT00740922

Intervention type: DRUG
Intervention: Sterile becaplermin gel vs. sterile placebo gel treatment 1
Description: Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
Study: NCT02816125

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acid
Description: SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
Study: NCT02624011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 days of habitual physical activity followed by 7 days of reduced physical activity
Description: Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
Study: NCT03111264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP
Description: The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills.
Study: NCT02983240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Uterine Pacemaker
Description: The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
Study: NCT03461471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise intervention
Study: NCT01531998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8.
Study: NCT03111264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP
Description: The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMP+
Description: The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
Study: NCT03968341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients
Description: A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information.
Study: NCT01555905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold PEP or IMT device Phillips-Respironics
Description: The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
Study: NCT03695393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Therapy
Description: The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
Study: NCT04280887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPad
Description: Ultrasound bed wetting alarm
Study: NCT02961517

Intervention type: OTHER
Intervention: Questionnaire
Description: Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
Study: NCT00326417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 150mg
Description: A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 100mg
Description: A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
Study: NCT01898364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402666
Description: Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
Study: NCT04699214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar (recombinant human endostatin injection)
Description: The experimental group is Endostar combined with AI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endostar (recombinant human endostatin injection)
Description: The experimental group is Endostar combined with AI
Study: NCT03050814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg intravenous (IV) over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (FU)
Description: 400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (FU)
Description: 400mg/m\^2 (only Arm A) intravenous (IV) bolus on day 1. Part of the standard of care therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m\^2 (Arm A) or 68mg/m\^2 (Arm B) intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
Study: NCT01531998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
Study: NCT03999580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance
Study: NCT04699214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy AI
Description: AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
Study: NCT03050814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (FU)
Description: 2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (FU)
Description: 2400 mg/m\^2 (Arm A and B) intravenous (IV) over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the standard of care therapy.
Study: NCT04421924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thrombelastogram
Description: Patients in the TEG group will receive prothrombin complex concentrates (PCC) at a dose of 10 IE/kg of ideal body weight, when R-time was greater than 40 minutes (2400 sec) and they will receive platelet transfusion in the amount of 1 apheresis unit when MA was below 30 mm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard of care
Description: 2) In the SOC group, patients will receive PCC at the dose of 10 IE /kg of ideal body weight when the PT is below 50% and/or INR\>1.8 and/or received platelet transfusion in the amount of 1 apheresis when platelet count is below 50 G/L
Study: NCT02438904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Positive Stem Cell Infusion
Description: Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi device
Description: Miltenyi device is used for CD34+ cell infusions) to patients who experience poor graft function after stem cell transplantation (SCT).
Study: NCT04223401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention
Study: NCT02808741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 SDD
Description: Pharmacokinetics area under curve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR
Description: Pharmacokinetics area under curve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR Fasting
Description: Pharmacokinetics area under curve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 IR Fed
Description: Pharmacokinetics area under curve
Study: NCT04111107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Agent
Description: Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care Regimens
Description: Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
Study: NCT03586518

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.

Intervention type: PROCEDURE
Intervention: Cardiac explantation
Description: A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.

Intervention type: DIAGNOSTIC_TEST
Intervention: 48-Hour continuous cardiac monitoring
Description: Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
Study: NCT04111107

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Gen Sequencing Report
Description: 1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.